But incredibly, thanks to ancient Roman engineering which helped to direct the overflowing waters of the dam, the deluge was diverted down a hillside and away from the town of Almonacid de la Cuba.

Além do resgate de novelas clássicas, a plataforma estreia documentários imperdíveis, como o cantor Belo, o novo talk show de Angélica, filme nacional exclusivo, e a terceira temporada da ...

O Monte Fuji ainda está sem neve, tornando este o momento mais tardio do ano em que a montanha permaneceu sem neve desde que os registros começaram há 130 anos. Os picos da montanha mais alta ...

Um desses escritores é Alexandre Dumas, e basta mencionarmos duas das suas obras mais conhecidas, mais lidas e intemporais, Os Três Mosqueteiros e O Conde de Monte Cristo. Ambas foram já levadas ao ...

The Department of Water and Sanitation’s latest weekly report revealed a significant decline in the country’s dam water capacity levels. 31 dams nationally recorded levels of under 50% of ...

After years of controversy and construction, British Columbia’s Site C dam has begun generating power. BC Hydro said Monday that the first of six generating units at the hydroelectric dam on the ...

Oct 28 (Reuters) - Swiss pharmaceutical giant Novartis (NOVN.S), opens new tab will pay Monte Rosa Therapeutics (GLUE.O), opens new tab $150 million upfront payment for a global license to develop ...

BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines ...

Don’t stop Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, developed using ...

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) stock is trading higher on Monday after the company announced a global exclusive development and commercialization license agreement with Novartis AG ...

“Esperamos que as pessoas de todo o Japão e do mundo desfrutem da grandiosidade do Monte Fuji”, comentou a organizadora do evento.

Novartis will pay $150 million to gain rights to “molecular glue degraders” being developed by biotechnology company Monte Rosa Therapeutics to target an immune signaling protein, known as VAV1, that ...